Veracyte acquires C2i Genomics

FDA approves Anktiva for non-muscle-invasive bladder cancer

FDA has approved ImmunityBio’s Anktiva (N-803, or nogapendekin alfa inbakicept-pmln) plus Bacillus Calmette-Guérin for the treatment of patients with BCG-unresponsive non-muscle-invasive bladder cancer with carcinoma in situ, with or without papillary tumors.

April 26, 2024

Vol.50 No.17

In Brief

Andrew Smith named chair of St. Jude Diagnostic Imaging Department

Andrew Smith was named chair of St. Jude’s Diagnostic Imaging Department. He succeeds Beth McCarville, who was interim chair of the department since the death of Zoltan Patay, who held the position from 2017 to 2022.

April 19, 2024

Vol.50 No.16

In Brief

ACCC establishes bladder cancer care resource

The Association of Community Cancer Centers has established a new e-course, Implementing Shared Decision-Making in Bladder Cancer Care, as part of its resources for cancer care centers to access evidence-based health literacy principles and shared decision-making strategies to reduce disparities in bladder cancer care.

January 12, 2024

Vol.50 No.02

Clinical Roundup

Women at high risk of breast cancer find novel decision-aid tool helpful, pilot study shows

A decision-making aid to help women at high risk of breast cancer decide whether to add MRIs to their screening regimen has proved popular with both patients and doctors alike in early testing.

December 15, 2023

Vol.49 No.46

Drugs & Targets

AnHeart, Foundation Medicine form collaboration focused on NSCLC diagnostic

AnHeart Therapeutics and Foundation Medicine Inc. have entered a strategic collaboration for the development and regulatory approval of Foundation Medicine’s tissue- and liquid-based comprehensive genomic profiling tests, FoundationOne CDx and FoundationOne Liquid CDx, as companion diagnostics for AnHeart’s investigational next-generation ROS1 inhibitor, taletrectinib, in the United States.

December 15, 2023

Vol.49 No.46